The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

  1. Billings, L.K.
  2. Agner, B.F.R.
  3. Altuntas, Y.
  4. Grøn, R.
  5. Halladin, N.
  6. Klonoff, D.C.
  7. Tentolouris, N.
  8. Jódar, E.
Revista:
Journal of Diabetes Science and Technology

ISSN: 1932-2968

Any de publicació: 2020

Volum: 15

Número: 3

Pàgines: 636-645

Tipus: Article

DOI: 10.1177/1932296820906888 GOOGLE SCHOLAR
Font de les dades: Scopus